Therapeutic response of benzodiazepine, orphenadrine citrate and occlusal splint association in TMD pain.
Loss of function, muscle inflammation, and pain are some of the signs and symptoms of temporomandibular dysfunction (TMD). Pharmacological strategies to minimize the clinical manifestation of these disorders often focus on blocking or inhibiting the pain-causing symptom. Resources such as muscle-relaxants, anxiety-relief drugs, and splint therapy are often used to reduce muscular hyperactivity related to TMD muscle pain. This study compares the effect of a randomly ordered association of occlusal splint therapy (S), nonsteroid anti-inflammatory with a muscle-relaxant drug (orphenadrine citrate) (O), and an anxiety-relief drug (benzodiazepine) (B), to ease painful TMD muscle symptoms. Clinical and anamnestic analyses were recorded in accordance with the Helkimo TMD index and applied before and after treatments. Twenty-one group two Helkimo TMD adult female patients were treated, all of whom were subjected to the three random therapeutic associations proposed: SBO, BOS, and OSB. The same operator applied the three specific associations over a period of 21 days in the proposed sequence, seven days for each therapy. The results show that all the groups presented the best results in terms of relief from pain after the therapeutic association (28.5% showed a decrease and 47.6% showed an absence of symptoms). No significant difference was observed among association therapeutic protocols.
Rizzatti-Barbosa
Célia M
CM
Faculty of Odontologia de Piracicaba, Dept de Prótese e Periodontia, Avenida Limeira, 901 Bairro Areiäo, CEP 13414.900 Piracicaba, SP, Brazil. rizzatti@fop.unicamp.br
Martinelli
Denise A
DA
Ambrosano
Gláucia M B
GM
de Albergaria-Barbosa
José R
JR
D000328:Adult; D014151:Anti-Anxiety Agents / Q000627:therapeutic use*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D001569:Benzodiazepines; D002985:Clinical Protocols; D005157:Facial Pain / Q000188:drug therapy / Q000628:therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008410:Masticatory Muscles / Q000187:drug effects; D009125:Muscle Relaxants, Central / Q000627:therapeutic use*; D017090:Occlusal Splints; D009966:Orphenadrine / Q000627:therapeutic use*; D018709:Statistics, Nonparametric; D013705:Temporomandibular Joint Disorders / Q000188:drug therapy / Q000628:therapy*
D014151:Anti-Anxiety Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D009125:Muscle Relaxants, Central; D001569:Benzodiazepines; D009966:Orphenadrine